MAP2K1 and colorectal carcinoma: Indeed, combined inhibition of MEK1/2 (trametinib) plus Wnt (LGK974 inhibitor) leads to the strong growth inhibitory effect than trametinib or LGK974 alone in EIF3H-high CRC PDX model.